Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
Crossref DOI link: https://doi.org/10.1007/s11523-016-0440-y
Published Online: 2016-05-19
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pavel, Marianne
Unger, Nicole
Borbath, Ivan
Ricci, Sergio
Hwang, Tsann-Long
Brechenmacher, Thomas
Park, Jinhee
Herbst, Fabian
Beaumont, Jennifer L.
Bechter, Oliver
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Text and Data Mining valid from 2016-05-19